Potassium-Competitive Acid Blocker: Novel Class of Anti-
Acid Drug
Volume 2 - Issue 2
Jaeyong Han MD1,2, Seung Hun Lee MD3 and Tong Wang MD1*
-
Author Information
Open or Close
- 1 Department of Cellular and Molecular Physiology, Yale University, New Haven, CT, USA
- 2 Department of Internal Medicine, Seoul Bon Clinic, Seoul, Korea
- 3 Department of Internal Medicine, Section of Nephrology, New Haven, USA
*Corresponding author:
Tong Wang, Department of Cellular and Molecular Physiology, New Haven, USA
Received:March 09, 2019; Published: March 14, 2019
DOI: 10.32474/CTGH.2018.01.000131
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Over the past several decades, great progress has been made on understanding mechanisms of gastric acid secretion for
developing new anti-acid drugs. Until now most commonly used anti-acid drugs are histamine-2 receptor antagonists and proton
pump inhibitors (PPIs) for patients to control acid related disease. However, several clinical limitations of these drugs had been
reported. Recently, a new generation of potassium-competitive acid blockers (P-CABs) were launched for clinical use. It has been
shown that these new drugs are more convenient and powerful to treat gastric acid-related diseases. In this article, we briefly
reviewed the clinical use of this new anti-acid drug P-CAB.
Keywords:Potassium-competitive Acid Blocker; Potassium channel; H+/K+-ATPase
Abstract|
Introduction|
Discussion|
Conclusion|
References|